DecisionDx-UM is the most widely used prognostic test in uveal melanoma in the U.S. It is used to predict risk of a patient’s tumor spreading in five years. According to studies published in Clinical Ophthalmology and Journal of Oncology, the DecisionDx-UM test has a significant impact on the management of uveal melanoma. Ophthalmologists report that they are more likely to increase frequency of disease monitoring or recommend clinical trials for those patients whose test results showed they were at high risk of metastasis.
The DecisionDx-UM test is extremely valuable in guiding a patient’s care following treatment of the original eye tumor. It measures the activity or “expression” of certain genes within the tumor to determine its risk profile, or Class: